THE WOODLANDS, Texas, April 10, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced
that the Company held a meeting with the FDA to discuss the progress and next steps in the development of Proellex® (telapristone
acetate) for the treatment of uterine fibroids. Shortly before the meeting, the Company was notified that the meeting would
be a type C/Guidance meeting, rather than a type B/End of phase 2 meeting as previously anticipated. At the meeting, the FDA
confirmed that Proellex® will continue on the current partial clinical hold while they consult with liver experts within the FDA
regarding previously disclosed effects on the liver. Further, the FDA agreed to accept additional information from the
Company and its panel of liver experts for consideration by the FDA’s internal advisory liver team. The Company expects to submit
the additional information and a proposed clinical protocol within a month. The Company intends to announce further
information following receipt of additional guidance from the FDA.
Larry Dillaha, M.D., the Company’s President and Chief Executive Officer, commented, “The Company is pleased with the guidance
received from the FDA, and while we remain on the current partial clinical hold as the FDA internally reviews our data related to
the effect of Proellex® on the liver, we will proceed with our development plans by submitting additional phase 2 protocols to the
FDA for their review. We are committed to working closely with the FDA as we further our development program for
Proellex®.”
About Repros Therapeutics Inc.®
Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat
male and female reproductive disorders.
Forward-Looking Statements
Any statements made by the Company that are not historical facts contained in this release are forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks,
uncertainties and other factors that could cause the Company’s actual results, performance or achievements to differ materially
from those expressed or implied by such forward-looking statements. These statements often include words such as “may,” “will,”
“expect,” “anticipate,” “continue,” “estimate,” “project,” “intend,” “believe,” “plan,” “seek,” “could,” “can,” “should” or similar
expressions. These statements are based on assumptions that the Company has made in light of the Company’s experience in the
industry, as well as the Company’s perceptions of historical trends, current conditions, expected future developments and other
factors the Company believes are appropriate in these circumstances. Forward-looking statements include, but are not limited to,
those relating to ongoing and future clinical studies and the timing and results thereof, the Company’s plans to communicate with
and submit further information to the FDA, possible submission of one or more NDAs and the commercial potential of Proellex® ,
risks relating to the Company’s ability to protect its intellectual property rights and such other risks as are identified in the
Company’s most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are
available on request from Repros Therapeutics or at www.sec.gov. Repros disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please visit the Company’s website at http://www.reprosrx.com.
CONTACT: Investor Relations: Thomas Hoffmann The Trout Group (646) 378-2931 thoffmann@troutgroup.com
